Jun. 13 at 5:21 PM
$ASRT No market confidence in ASRT. Management knows it, seem content to letting stock ride till brink of being removed from NASDAQ, then recreate the same private offering of newly created shares (increasing float) it’s done in past, then once the purchaser has a chance to sell them at a profit a few months later, they’ll turn around and complete a R/S. Bait & switch, & only ones who’ll get screwed are ASRT shareholders. Same day dosing approval…anybody have the cure for aging or to go back in time, cause you’ll need it by time same day gets approved & begins to show any huge legitimate revenue. If ASRT wants to be a player again, they’ll turn around just have to admit it’s not in NSAID’s alone, go back to being both an Opioid & NSAID player. They took a chance & abandoned that model that made them a
$30+ stock & look what it got them, one private offering & R/S later.
$0.60 to
$0.70 stock. You know it’s bad when your company stock is undervalued & still no one buying it. 🥃
